Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-89894 (SYH2039) Tablets in Patients With Advanced Solid Tumors

NCT06568614 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT06568614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06568614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-89894 (SYH2039) Tablets in Patients With Advanced Solid Tumors
Lead sponsor
BeOne Medicines
Phase
Phase 1
Overall status
Terminated
Start date
October 12, 2024
Completion date
April 13, 2026
Enrollment
29 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic mtap-deleted solid tumors